MapLight reports $463.4m cash as schizophrenia Phase 3 prep begins; Alzheimer's psychosis readout slips to 2028
The US neuropsychiatry biotech is preparing a second late-stage schizophrenia study and says it may seek partners or other funding for its autism candidate.
16 Nov 2026 · MapLight Therapeutics, Inc. MPLT · Company news
MapLight Therapeutics said on 16 November 2026, alongside third-quarter results, that it has begun start-up work on ZEPHYR-2, a confirmatory Phase 3 study of ML-007C-MA in schizophrenia. The company reported cash of $463.4 million at the end of the quarter.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
or
Company's press release (SEC filing): MapLight Therapeutics, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
More Pipeline & R&DAll →
Pipeline & R&D
Summit starts Phase III HARMONi-10 of ivonescimab against durvalumab in Stage III NSCLC
18 Nov 2026 · Summit Therapeutics Inc. SMMT · Company news
Pipeline & R&D
NeOnc deck reports Phase 2a intranasal NEO100 results in recurrent IDH1-mutant glioma
18 Nov 2026 · Neonc Technologies Holdings, Inc. NTHI · Company news
Pipeline & R&D
Optimi Health seeks to make psilocybin depression study randomised Phase 2b; MDMA Phase 3 planned
18 Nov 2026 · Optimi Health Corp. OPTH · Company news
Pipeline & R&D
Can-Fite completes dosing in interim cohort of Phase III piclidenoson psoriasis trial
18 Nov 2026 · Can-Fite BioPharma Ltd. CANF · Company news
Pipeline & R&D
Inhibrx reports 62.7% response rate for ozekibart combination in relapsed Ewing sarcoma
17 Nov 2026 · Inhibrx Biosciences, Inc. INBX · Company news
Pipeline & R&D
Adagene and City of Hope launch Phase 1 trial of ivonescimab plus muzastotug in colorectal cancer
17 Nov 2026 · Adagene Inc. ADAG · Company news